Objective To assess the efficiency and safety of alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis (GIOP).Methods The electronic databases of PubMed,EMBASE,Cochrane Library,Web of Science,Chinese BioMedical Literature Database (CBM) and Wanfang Data were searched for all randomized controlled trials (RCT) of alendronate vs.placebo.Two reviewers independently selected trials for inclusion,assessed trial quality using Jadad's scale and extracted the data.RevMan 5.1 software was used for data synthesis and Meta-analysis.Results Seven studies with 1111 patients were included.Compared with placebo,alendronate significantly increased bone mineral density (BMD) at the lumbar spine[MD ＝3.35,95％CI (2.67-4.02),P =0.000] and the femoral neck[MD =1.90,95％ CI (0.89-2.92),P =0.000] after 12 months of therapy.After 24 months of therapy,alendronate significantly increascd BMD at the lumbar spine [MD =3.91,95％ CI (2.37-5.45),P =0.000],but not at the femoral neck [MD =1.91,95％ CI (-1.15-5.02),P =0.22].Compared with placebo,no significant reduction was found by the use of alendronate in the incidence of vertebral fractures [RR =1.00,95％ CI (0.49-2.07),P =0.99] or nonvertebral fractures[RR ＝ 1.02,95％ CI (0.49-2.14),P =0.95].No difference was shown with the adverse event between the two groups[RR =0.97,95％ CI (0.90-1.05),P =0.47].Conclusions Alendronate is effective for the prevention and treatment of glucocorticoid-induced bone loss at the lumbar spine and the femoral neck with relatively good safety profile.Yet,there is no significant difference between the two groups in reducing the incidence of vertebral fractures and non-vertebral fractures.Large-scale RCT designed to observe whether different lengths of alendronate therapy will influence the efficiency should be conducted in the future and to further explore whether it can reduce the incidence of fractures.

Objective To investigate the influencing factors of survival rate in patients with myocardial infarction treated with intra-aortic balloon pump (IABP).Methods A total of 94 myocardial infarction patients with IABP in our hospital were selected,and were divided into survival group and death group according to the survival status.Clinical data,results of coronary angiography,emergency PCI results were compared,and the relevant influencing factors were analyzed by multivariate regression analysis.Results The average age,ratio of Killips Ⅲ/Ⅳ,CK-MB peak showed significant differences between two groups (P ＜ 0.05).Significant differences were seen in the proportion of patients merging LM disease and blood flow with class TIMI3 after PCI in the two groups (P ＜ 0.05).Multivariate regression analysis showed that the age,Killips Ⅲ/Ⅳ,CK-MB peak,blood flow with class TIMI3 after PCI,and merging LM lesions were the risk factors of survival status for patients.Conclusion The survival status of patients with IABP are mainly influenced by age,Killips Ⅲ/Ⅳ,CK-MB peak,blood flow with class TIMI3 after PCI,and merging LM lesions and other factors.

Objective To investigate the influencing factors of survival rate in patients with myocardial infarction treated with intra-aortic balloon pump (IABP).Methods A total of 94 myocardial infarction patients with IABP in our hospital were selected,and were divided into survival group and death group according to the survival status.Clinical data,results of coronary angiography,emergency PCI results were compared,and the relevant influencing factors were analyzed by multivariate regression analysis.Results The average age,ratio of Killips Ⅲ/Ⅳ,CK-MB peak showed significant differences between two groups (P ＜ 0.05).Significant differences were seen in the proportion of patients merging LM disease and blood flow with class TIMI3 after PCI in the two groups (P ＜ 0.05).Multivariate regression analysis showed that the age,Killips Ⅲ/Ⅳ,CK-MB peak,blood flow with class TIMI3 after PCI,and merging LM lesions were the risk factors of survival status for patients.Conclusion The survival status of patients with IABP are mainly influenced by age,Killips Ⅲ/Ⅳ,CK-MB peak,blood flow with class TIMI3 after PCI,and merging LM lesions and other factors.

In the era of evidence-based medicine, it is necessary to explore the unique advantages of traditional Chinese medicine (TCM) based on standardized technical methods and operating procedures in order to achieve the modernization and internationalization of TCM and benefit all humanity. The proposal of a three-pronged evidence system combining TCM theory, human experience and experimental evidence marks an important progress in the thinking method of the TCM evaluation system. The multi-evidence body integrated through appropriate methods provides a strong support for the clinical guideline recommendations and evidence-based health decision-making in TCM. Based on the current methodological progress of international evidence synthesis and grading, this paper proposes a novel approach for integrating multi-evidence in TCM: the MERGE framework. The aim is to establish a solid foundation for the development of this methodology and provide guidance for the advancement of evidence-based medicine framework in TCM.